Brian Cheng
Stock Analyst at JP Morgan
(1.56)
# 3,503
Out of 5,008 analysts
65
Total ratings
48.98%
Success rate
-10.69%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Brian Cheng
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ABSI Absci | Initiates: Overweight | n/a | $3.74 | - | 1 | Oct 2, 2025 | |
| IMVT Immunovant | Maintains: Overweight | $37 → $33 | $16.11 | +104.84% | 4 | Sep 30, 2025 | |
| CGON CG Oncology | Maintains: Overweight | $41 → $47 | $38.00 | +23.68% | 2 | Sep 26, 2025 | |
| ROIV Roivant Sciences | Maintains: Overweight | $16 → $20 | $16.12 | +24.07% | 7 | Sep 18, 2025 | |
| CRSP CRISPR Therapeutics AG | Initiates: Overweight | $70 | $70.62 | -0.88% | 1 | Sep 18, 2025 | |
| PGEN Precigen | Upgrades: Neutral | n/a | $3.31 | - | 3 | Aug 15, 2025 | |
| IMNM Immunome | Maintains: Overweight | $23 → $22 | $13.82 | +59.19% | 3 | Aug 7, 2025 | |
| ALLO Allogene Therapeutics | Downgrades: Neutral | n/a | $1.35 | - | 4 | Aug 4, 2025 | |
| AAPG Ascentage Pharma Group International | Initiates: Overweight | n/a | $38.88 | - | 1 | Mar 27, 2025 | |
| PTGX Protagonist Therapeutics | Maintains: Overweight | $53 → $57 | $65.49 | -12.96% | 5 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $45 → $13 | $20.44 | -36.40% | 4 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $3.93 | - | 3 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $18 | $16.50 | +9.09% | 2 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $27 → $28 | $12.03 | +132.75% | 4 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $39 → $33 | $5.41 | +509.98% | 2 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $16 → $6 | $2.95 | +103.39% | 2 | May 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $125 | $7.96 | +1,470.35% | 3 | Mar 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $17 → $14 | $0.80 | +1,661.01% | 3 | Sep 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | n/a | $4.31 | - | 3 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $20 → $6 | $0.85 | +603.32% | 2 | Jun 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $1.73 | - | 1 | Dec 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $2.50 | - | 2 | Dec 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $71 → $85 | $20.47 | +315.24% | 2 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $21 | $6.95 | +202.16% | 1 | Aug 3, 2021 |
Absci
Oct 2, 2025
Initiates: Overweight
Price Target: n/a
Current: $3.74
Upside: -
Immunovant
Sep 30, 2025
Maintains: Overweight
Price Target: $37 → $33
Current: $16.11
Upside: +104.84%
CG Oncology
Sep 26, 2025
Maintains: Overweight
Price Target: $41 → $47
Current: $38.00
Upside: +23.68%
Roivant Sciences
Sep 18, 2025
Maintains: Overweight
Price Target: $16 → $20
Current: $16.12
Upside: +24.07%
CRISPR Therapeutics AG
Sep 18, 2025
Initiates: Overweight
Price Target: $70
Current: $70.62
Upside: -0.88%
Precigen
Aug 15, 2025
Upgrades: Neutral
Price Target: n/a
Current: $3.31
Upside: -
Immunome
Aug 7, 2025
Maintains: Overweight
Price Target: $23 → $22
Current: $13.82
Upside: +59.19%
Allogene Therapeutics
Aug 4, 2025
Downgrades: Neutral
Price Target: n/a
Current: $1.35
Upside: -
Ascentage Pharma Group International
Mar 27, 2025
Initiates: Overweight
Price Target: n/a
Current: $38.88
Upside: -
Protagonist Therapeutics
Mar 4, 2025
Maintains: Overweight
Price Target: $53 → $57
Current: $65.49
Upside: -12.96%
Feb 28, 2025
Downgrades: Neutral
Price Target: $45 → $13
Current: $20.44
Upside: -36.40%
Dec 16, 2024
Downgrades: Underweight
Price Target: n/a
Current: $3.93
Upside: -
Dec 16, 2024
Upgrades: Overweight
Price Target: $18
Current: $16.50
Upside: +9.09%
Nov 7, 2024
Maintains: Overweight
Price Target: $27 → $28
Current: $12.03
Upside: +132.75%
Jul 31, 2024
Maintains: Overweight
Price Target: $39 → $33
Current: $5.41
Upside: +509.98%
May 2, 2024
Downgrades: Neutral
Price Target: $16 → $6
Current: $2.95
Upside: +103.39%
Mar 19, 2024
Upgrades: Neutral
Price Target: $125
Current: $7.96
Upside: +1,470.35%
Sep 25, 2023
Maintains: Overweight
Price Target: $17 → $14
Current: $0.80
Upside: +1,661.01%
Aug 10, 2023
Upgrades: Neutral
Price Target: n/a
Current: $4.31
Upside: -
Jun 1, 2023
Downgrades: Neutral
Price Target: $20 → $6
Current: $0.85
Upside: +603.32%
Dec 16, 2022
Initiates: Neutral
Price Target: n/a
Current: $1.73
Upside: -
Dec 7, 2022
Downgrades: Underweight
Price Target: n/a
Current: $2.50
Upside: -
Aug 10, 2021
Maintains: Overweight
Price Target: $71 → $85
Current: $20.47
Upside: +315.24%
Aug 3, 2021
Initiates: Overweight
Price Target: $21
Current: $6.95
Upside: +202.16%